Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of LT3001 injection in acute ischemic stroke
CTR20263022Phase 2Active
- Sponsor
- Shun Tian Medical & Biotechnology
- Start
- Aug 2026
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of odatroltide in ischemic stroke (3 arms), sponsored by Shun Tian Medical & Biotechnology. Primary endpoint: Proportion of participants with modified Rankin Scale score 0-1. Started Aug 2026; status: active.
02
Drugs
odatroltide
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on CTR20263022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20263022.